Dubai Science Park to host new AI longevity research laboratory
The Longevity AI Research Laboratory, scheduled to open in the fourth quarter of 2026
03 August, 2026
TT
16
Dubai-based longevity healthcare company Longevium has raised $7m in its first investment round and begun construction of an artificial intelligence-powered research laboratory at Dubai Science Park, as it looks to accelerate the development of preventive healthcare technologies and position the UAE at the forefront of longevity medicine.
The Longevity AI Research Laboratory, scheduled to open in the fourth quarter of 2026, will serve as a dedicated research and development centre rather than a clinical facility, bringing together artificial intelligence, biomedical research and clinical practice to develop technologies that predict health risks, measure biological ageing and extend healthy lifespans.
The project aligns with Dubai’s broader ambitions to become a global hub for longevity research and preventive healthcare, supporting the vision of the Dubai Longevity Authority and the emirate’s growing focus on healthcare innovation.
The newly secured funding will be used to establish the laboratory and expand research into next-generation diagnostics, longevity technologies and clinical research programmes.
Among the key research areas will be AI-powered digital twins, enabling physicians to simulate personalised treatment protocols before clinical use, alongside regenerative medicine, tissue engineering and advanced cell therapies aimed at restoring organ function.
The laboratory will also investigate robotic diagnostic technologies, including swallowable imaging capsules, AI-powered skin cancer scanners and smart contact lenses capable of monitoring health through tear-fluid analysis.

Another area of focus will be noble gas therapy, with research into the therapeutic potential of xenon, argon, helium and krypton for applications ranging from organ protection and stress-related conditions to neurodegenerative diseases.
Longevium also plans to develop what it describes as a regional reference AI model for biological ageing by integrating laboratory biomarkers, imaging, body composition analysis and wearable device data.
“Our mission is to make the world’s most advanced longevity innovations accessible to more people and help create a future in which healthy human lifespans of up to 200 years may become possible,” said Dr. Ksenia Butova, founder and CEO of Longevium.
The research hub will build on technologies already deployed across Longevium’s three Dubai clinics, including its AI physician assistant, Doctor Deep, and a biological age assessment application.
The company’s clinical network, located in Jumeirah 3, Jumeirah Lake Towers and Jumeirah Village Circle, has treated more than 30,000 patients and employs nearly 100 physicians and specialists, providing a foundation for long-term clinical data collection and validation of emerging preventive healthcare technologies.
Longevium said it is recruiting international researchers and scientists while seeking partnerships with academic institutions, healthcare providers, investors and technology companies working across longevity medicine, AI-enabled diagnostics and preventive healthcare.





















